FDA Approves Botox for Overactive Bladder

When patients don't respond to standard treatments

TUESDAY, Jan. 22 (HealthDay News) -- U.S. Food and Drug Administration approval of Botox (onabotulinumtoxinA) has been expanded to include adults with overactive bladder who don't respond to anticholinergics.

In a clinical study, people treated with Botox after 12 weeks had urinary incontinence 1.6 to 1.9 times less per day than people treated with a placebo, the FDA said.

The most common adverse reactions recorded during the study included urinary tract infection, painful urination, and urinary retention. People who develop urinary retention may have to use a catheter until the situation resolves, the agency said.

Botox has been approved for several other uses, notably to treat facial wrinkles. The product is made by Allergan Inc., based in Irvine, Calif.

More Information

Copyright © 2013 HealthDay. All rights reserved.

Powered by

Featured Jobs



Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member